substance use
The alliance aims to mitigate the human and economic price related to the improper prescribing and dispensing of controlled substances.
The company announced it had raised $20 million in Series B funding in May last year.
The company plans to use the funding to expand into new regions. It aims to operate nationwide by 2023.
New data published in JMIR outlines encouraging results from a modified version of the text-based chatbot app.
The company formerly focused its efforts on enabling chronic pain management care.